Predictive Oncology Inc. (POAI) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline.
Price
| Price | $4.91 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.84 |
| EV / EBITDA | -0.50 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -488.50% |
| Return on Invested Capital | -57.56% |
| Return on Assets | -440.73% |
| Gross Margin | 7.15% |
| Operating Margin | -1483.87% |
| Net Margin | -7242.42% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 1.45 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 2.62 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| POAI | Predictive Oncology Inc. | $4M | 2.84 | -488.5% | |
| 0R29.L | Intuitive Surgical, Inc. | $135.9B | 74.05 | 11.86 | 17.8% |
| ISRG | Intuitive Surgical, Inc. | $135.1B | 44.13 | 7.62 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $52.5B | 33.21 | 2.19 | 6.6% |
| BDX | Becton, Dickinson and Company | $49.0B | 54.89 | 2.05 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 22.81 | 5.23 | 23.9% |
| 0KW4.L | ResMed Inc. | $31.1B | |||
| MDLN | Medline Inc. | $27.6B | 38.36 | 2.44 | 10.8% |
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of POAI: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks